Balmanoukian, A., Zhang, Z., Jeter, S., Slater, S., Armstrong, D. K., Emens, L. A., … Stearns, V. (2009). African American women who receive primary anthracycline- and taxane-based chemotherapy for triple-negative breast cancer suffer worse outcomes compared with white women. J Clin Oncol, 27(22), e35–e37. https://doi.org/10.1200/JCO.2008.21.5509

Balmanoukian, Ani, Zhe Zhang, Stacie Jeter, Shannon Slater, Deborah K. Armstrong, Leisha A. Emens, John H. Fetting, et al. “African American women who receive primary anthracycline- and taxane-based chemotherapy for triple-negative breast cancer suffer worse outcomes compared with white women.” J Clin Oncol 27, no. 22 (August 1, 2009): e35–37. https://doi.org/10.1200/JCO.2008.21.5509.

Balmanoukian A, Zhang Z, Jeter S, Slater S, Armstrong DK, Emens LA, et al. African American women who receive primary anthracycline- and taxane-based chemotherapy for triple-negative breast cancer suffer worse outcomes compared with white women. J Clin Oncol. 2009 Aug 1;27(22):e35–7.

Balmanoukian, Ani, et al. “African American women who receive primary anthracycline- and taxane-based chemotherapy for triple-negative breast cancer suffer worse outcomes compared with white women.” J Clin Oncol, vol. 27, no. 22, Aug. 2009, pp. e35–37. Pubmed, doi:10.1200/JCO.2008.21.5509.

Balmanoukian A, Zhang Z, Jeter S, Slater S, Armstrong DK, Emens LA, Fetting JH, Wolff AC, Davidson NE, Jacobs L, Lange J, Tsangaris TN, Zellars R, Gabrielson E, Stearns V. African American women who receive primary anthracycline- and taxane-based chemotherapy for triple-negative breast cancer suffer worse outcomes compared with white women. J Clin Oncol. 2009 Aug 1;27(22):e35–e37.